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The aims of this study were to prepare novel transfersomes (TFs) for tacrolimus to treat
atopic dermatitis, and to observe the therapeutic effects on mice atopic dermatitis, as
compared to commercial tacrolimus ointment (Protopic) and liposomes-gel. Different
kinds of surfactantsdsodium cholate, Tween 80 and Span 80 were investigated to prepare
TFs respectively. TFs-Tween 80 was selected as the optimal carrier owing to the best
deformability and the highest drug retentions. Entrapment efficiency and diameter were
also evaluated. The optimized TFs were further made into gel and in vitro drug release of
TFs-gel after 24 h was higher than the commercial ointment. Cumulative drug release from
TFs-gel after 12 h in vitro was 37.6%. The optimized TFs-gel illustrated remarkably highest
drug skin retentions when compared with liposomes-gel and commercial ointment in vivo
skin retention experiments. The amounts of tacrolimus in epidermis and dermis from TFs-
gel were 3.8 times and 4.2 times respectively as much as ointment, while liposomes-gel
was only 1.7 times and 1.4 times respectively as compared to ointment. Topical applica-
tion of TFs-gel displayed the best therapeutic effect on mice atopic dermatitis induced by
repeated topical application of 2,4-dinitrofluorobenzene. Thus TFs displayed superior
performance and effective skin target for topical delivery of tacrolimus.
ª 2013 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. All
rights reserved.1. Introduction increasing serum IgE level and marked perivascular T-cellAtopic dermatitis (AD) was a chronic and relapsing skin dis-
ease with severe itching and eczematous lesions [1]. Theatory of Advanced Drug
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damaged the skin barrier and exacerbated the dermatitis [4].
Tacrolimus, also known as FK506, was a powerful macrolide
lactone immunosuppressant isolated from Streptomyces tsu-
kubaensis and showed notably therapeutic efficacy for
immune-inflammatory conditions including AD [5,6]. Tacro-
limus functioned primarily on T-cells in affected skin,
restraining T-cells activation and controlling the release of
pro-inflammatory cytokines. Moreover, tacrolimus could in-
fluence other immune cells pathways that were related to the
pathogenesis of AD, such as blocking cytokine generation and
release of basophils, eosinophils and mast cells, decreasing
the number of inflammatory dendritic epidermal cells in AD
injured layers [7].
At present, there was only one tacrolimus commercial
preparation for topical application, tacrolimus ointment. In
1999, tacrolimus ointment had been approved by the Food and
Drug Administration to treat moderate to severe cases of AD.
Current studies had also suggested that topical application of
ointment might be effective in the treatment of acute contact
dermatitis, erosive lichen planus, isolated ichthyosis linearis
circumflexa, and Lazarous and Kerdel [8]. However, physico-
chemical properties of tacrolimus, high molecular weight
(822.95 g/mol) and strong lipophilicity (partition coefficient
logP ¼ 3.96  0.83), made it difficult to overcome the skin
barrier and penetrate into deeper skin layers [9]. What’s more,
the skin barrier would extend at diseased regions [10]. It was
highly challenging to overcome the skin barrier-stratum cor-
neum (SC) and reach the dermis in sufficient active drug
concentrations. A novel delivery system which could help
more tacrolimus penetrate across SC and target site of action
was necessary to provide.
Transfersomes (elastic or ultraflexible liposomes) were a
new class of lipid vesicles introduced by Gregor et al. in 1992
[11]. TFsmight offer advanced local therapies with agents that
were unable to efficiently penetrate the SC via passive diffu-
sion. Ketoprofen in TFs formulation had gained marketing
approval by the Swiss Regulatory Agency [12]. TFs consisted of
lipids and a membrane softening agents, where lipids were
the major components of vesicle membrane and softening
agents functioned as a destabilizing factor to increase the
deformability of TFs membrane. The combination of appro-
priate lipids with membrane softening agents could enable
TFs to penetrate pores that were five times smaller than their
own diameters. Moreover, the diameters maintained even
after TFs passed through small pores against fragmentation
[13,14]. Surfactants were suggested as examples of softening
agents, such as sodium cholate (SDC), Span 80 and Tween 80Table 1 e Different kinds of surfactants and their influences on
Formulation namea EE% Particle size/nm
TFs-SDC 70.60  1.10 135.6  2.9
TFs-Tween 80 78.86  1.62 123.1  2.2
TFs-Span 80 83.88  2.36 260.6  4.0
Liposomes 71.76  1.29 159.7  3.5
a In addition to the different kinds of surfactants, the other ingredients o
FK506: 72 mg, vitamin E: 20 mg, PBS(pH6.5): 20 ml).[15]. When TFs dispersions were applied to skin non-
occlusively, the excess of applied water started to evaporate
immediately and osmotic gap was built up to facilitate TFs to
across the skin SC primary barrier [16]. The high deformability
and hydration driving force of TFs both allowed and prompted
the drug-loaded vesicles to across the skin barrier [17].
The present study was to screen a suitable surfactant for
TFs to enhance skin delivery of tacrolimus. Three kinds of
surfactants were investigated in the preparation of TFs. The
entrapment efficiency, particle size, deformability index and
drug retentions of different TFs were compared. The optimal
TFs were prepared to gel and drug release in vitro were
compared with liposomes-gel and ointment. Then the
amounts of tacrolimus depositing in different skin layers
in vivo percutaneous permeation and therapeutic effects on
mice AD models were used to evaluate the efficiency and su-
periority of TFs-gel.2. Materials and methods
2.1. Materials and animals
Tacrolimuswaspurchased fromHuadongpharmaceutical Co.,
Ltd. (Hangzhou, China). Protopic (0.1% tacrolimus ointment)
was produced by Astellas Toyama Co., Ltd. (Toyama city,
Japan). Lipoid E80 containing more than 80% phosphatidyl-
choline (PC) was bought from Shanghai Toshisun Biology &
Technology Co., Ltd. (Shanghai, China). 2,4-
Dinitrofluorobenzene (DNFB) was purchased from Xiya
Chemical Industry co., Ltd. (Chengdu, China). HPLC reagents
were supplied by Tedia Company Inc (Ohio, America). All other
chemicals and solvents were of analytical grade or better.
SD rats (male, 350e400 g) and KMmice (male, 20e23 g) were
obtained from the Laboratory Animal Center of Guangzhou
University of Chinese Medicine (Guangzhou, China) and
housed under specific pathogen-free conditions. The rats
were allowed to acclimatize for at least 3 days prior to any
study procedures. The study protocol was approved by the
Animal Ethics Committee of Guangdong Pharmaceutical
University.
2.2. Formulation of tacrolimus-loaded TFs
Tacrolimus-loaded TFs were prepared by thin film dis-
persionehydration method. Briefly, drug, lipoid E80, surfac-
tants and vitamin E were completely dissolved in round
bottom flask with 20 ml of dehydrated alcohol. The alcoholcharacteristics of vesicles (n[ 3).
Deformability index Drug retentions (mg/cm2)
6.25  0.09 5.11  0.38
9.22  0.17 6.66  0.68
7.93  0.14 5.87  0.51
4.30  0.06 4.22  0.32
f formulations were the same ( lipoid E80: 1.200 g, surfactant: 0.372 g,
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thin lipid film was obtained. The film was hydrated with
20 ml of pH 6.5 phosphate buffer for 1 h at the temperature of
20 C to get rude dispersions. The dispersions was sonicated
using a Scientz-IID sonicator (Scientz Biotechnology Co., LTD,
Ningbo, China) for 9 min under 400 w. Extrusion through
0.45 mm pore size Nylon-66 membranes was followed for size
reduction.
Three kinds of surfactants were inspected, that were SDC,
Tween 80 and Span 80. Liposomes loaded tacrolimus were
also formulated and the surfactant was substituted with
cholesterol. The resulting TFs dispersions and liposomes dis-
persions were in light blue opalescence, except TFs-SDC dis-
persions were in brown yellow which was the color of SDC
itself. Differences of TFs were listed in Table 1.2.3. Determination of drug encapsulation efficiency
The encapsulation efficiency (EE%) of TFs and liposomes was
determined using the dialysis technique for separating the
non-entrapped tacrolimus. 1 ml of tacrolimus-loaded TFs or
liposomes dispersions were dropped into a dialysis bag (mo-
lecular weight cut off: 10 kDa) immersed in 10 ml of 25% v/v
ethanol solution and shook at 50 rpm [18]. 0.5 ml of ethanol
solution was taken out after 8 h and analyzed by HPLC to ac-
count the mass of unentrapment drug (Wf). Then 1 ml of
tacrolimus-loaded TFs or liposomes dispersions were de-
emulsified with 25 ml methanol and the obtained solution
was detected as total drug in dispersion (Wt). The encapsula-
tion efficiency (EE%) could be counted by the following
equations:
EE% ¼Wt Wf
Wt
 100%
2.4. Characterization of tacrolimus-loaded TFs
2.4.1. Particle size distribution
Particle size distribution of TFs and liposomes were measured
using dynamic light scattering (BeckmanCoulter DelsaNano
C, USA). Samples were diluted by 1-fold with distilled water
beforemeasurement. All of samplesweremeasured 3 times at
25 C under a fixed scattering angle of 90.
2.4.2. Relative deformability
The relative deformability of TFs was compared with lipo-
somes by extrusion measurement [19]. Flexibility was
observed by extrusion of vesicles through 0.22 mm Nylon-66
syringe filters (Filtration area: 1.3 cm2, Jinteng Experiment
Equipment Co., Ltd, Tianjin, China) at a constant pressure of
0.2 MPa. The extrusion volume in 5 min was recorded for TFs
dispersions, liposomes dispersions, respectively. Deform-
ability index (DI) was counted using the following formula:
DI ¼ J  rv
rp
where, J ¼ the volume of the dispersions extruded during
5 min; rv ¼ the size of the vesicle; rp ¼ pore size of the filter.2.4.3. In vitro percutaneous permeation
Skin samples obtained from the abdominal region of male
SD rats were used to evaluate the in vitro permeation of
tacrolimus delivered via TFs, liposomes dispersions. The
permeation studies were conducted using the Franz diffu-
sion cells (Xiekai Scientific, China). The skin was mounted
on diffusion cells with the dermis facing the receptor
compartment and the surface area of skin was 3.14 cm2. The
same quality of dispersions was placed. Receptor compart-
ment was full of 25% alcohol solution. After 24 h, the
permeation experiment was end and receptor medium was
withdrawn waiting for detection. Skin samples were
removed and immersed in methyl alcohol waiting for
detection.
2.4.4. Microscopic morphology
Transmission electron microscopy (TEM) images were taken
employing a JEM-1400 microscope (JEOL, Japan) operating at
an accelerating voltage of 120 kV. The sample was prepared
according to Laouini’s work [20]. The optimized TFs disper-
sions were firstly diluted 10 times with distilled water and
dropped onto a carbon-coated copper grid. The excess
dispersion was removed with a filter paper after 1-min.
Negative staining using a 2% phosphotungstic acid solution
(w/w) was directly made on the deposit for 45 s. Then the air-
dried samples were directly examined under the TEM.
2.5. Formulation of vesicular gel
2.5.1. Preparation of vesicular gel
In order to make dispersion suitable for topical application,
TFs and liposomes dispersions were made into gel.
Carbopol940 was added into the distilled water and was
stirred over night with magnetic stirrer. TFs and liposomes
dispersionswere added to carbopolmixture introduced above.
The concentration of carbopol940 was 1% (wt.). Triethanol-
amine was put in to neutralize pH value of 6.0. Then vesicular
gel was obtained.
2.5.2. In vitro release of vesicular gel
In vitro release of vesicular gel was measured utilizing vertical
glass Franz diffusion cells introduced above. Nylon66 filters
(0.20 mm pore diameter, Millipore Isopore, USA) were bathed
in isopropyl myristate to imitate the lipophilic property of SC
[21]. Weighted quantity (0.3 g) of vesicular gel and tacrolimus
ointment were applied to the donor compartment while re-
ceptor compartment was full of 25% alcohol solution. Recep-
tor compartment was maintained at 32  0.5 C and stirred at
200 rpm constantly. Receptor solution was taken at pre-
determined time intervals.
2.6. In vivo percutaneous permeation
An area of 2  3 cm in the dorsal skin of SD rat was hair
removed. The same quality of vesicular gel and tacrolimus
ointment were applied evenly. After 24 h, the permeation
experiment was end and the rats were anesthetic by inha-
lation of chloroform. 1 ml of blood and skin over the site of
use were collected from each rat. The skin layers were
separated referring to the work of Babu et al. [22]. The SC was
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remained skin was frozen at 50 C and separated into
epidermis and dermis horizontally using a cryo-microtome
(CM1900 Leica, Germany). The epidermis layers were
removed by 4 sections 25 mm thick each. The portions left
were collected as dermis layers. Three parts of skin layers
were chopped and extracted in methanol with homogeniza-
tion (IKA Wiggens D-120, Germany). The samples were kept
refrigerated for 12 h and then centrifuged to get supernatant
for analysis of tacrolimus content. Blood sample process was
referred to Lee et al. [23].2.7. Pharmacodynamic study
Repeated topical applications of DNFBwere used to induce AD
with appropriate changes from the method presented by
Pokharel et al. [24]. Firstly, sensitization was caused by
applying 25 ml of 0.5%DNFB dissolved in acetone/olive oil (4:1)
to the hair-removed abdomen of mice once per day on a
continuous three-day. Then mice were bred for 3 days nor-
mally. At the sixth day, the backs of mice were unhaired with
an area of 2 2 cm. 40 ml of 0.25% DNFBwere placed uniformly
once per 3 days to stimulated AD. At the same time, 5 ml of
0.25% DNFB were applied to the inside of the right earlobe of
mice while the same quantity of acetone/olive oil (4:1) was
applied to the left side. Four times later, AD model was pre-
pared. It should be noted that blank control group was given
acetone/olive oil.
FK506 loaded TFs-gel group, liposomes-gel group and Pro-
topic group were spread with corresponding preparation
twice one day while the model group and blank control group
didn’t get any treatments. Administration dose was 0.25 g/
back and 0.05 g/earlobe.
After the final administration, morphological changes of
mice back skin, left and right ears were observed. The mice
were then sacrificed and ears of both sides were cut off using
a hole punching device (diameter as 6 mm). Mass and
thickness differences between left and right ear were used to
evaluate the induced ear swelling. Skin tissues from the
backs of mice were excised and subjected to histological
examination.2.8. Analytics
Tacrolimus was quantified using a Dionex Ultimate3000
HPLC system equipped with a LPG-3400SD quaternary
pump and a DAD-3000 diode array detector. The assay was
carried out at a wavelength of 210 nm, using a Agilent SB C8
column (4.6  250 mm, 5 mm) maintained at a temperature
of 60 C, with a mobile phase composed of acetonitrile/
water (60:40, v/v), a flow rate of 1 ml/min and injection
volume of 20 ml.2.9. Statistics
Statistical significance was determined by one-way ANOVA
followed by Student’s t-test as post hoc analysis. Differences
were considered as significant at p < 0.05.3. Results and discussion
3.1. Characterization of TFs
TFs were prepared by using three different kinds of surfac-
tants, namely SDC, Tween 80 and Span 80. Table 1 showed
the effects of different surfactants types on characterizations
of TFs.
3.1.1. Drug encapsulation efficiency
TFs consisting different kinds of surfactants displayed diverse
EE%. Maximum EE% (83.88%) was obtained from TFs-Span 80,
followed by TFs-Tween 80 (78.86%) and TFs-SDC (70.60%). The
phenomenon was similar to El Zaafarancy et al. [25].
The results could be explicated as that the entrapment of
lipophilic drug into lipid vesicles was facilitated by drug dis-
tribution coefficient between lipid phase and aqueous solu-
tion [26]. The HLB of Span 80, Tween 80 and SDC was 4.3, 15.0
and 16.7. Correspondingly, the affinity of surfactants with
lipids decreased in sequence. Based on the affinity of surfac-
tants with lipids and the strong lipophilic property of drug
(logP ¼ 3.96  0.83), tacrolimus would be more prevalent
dispersing in double-layer lipids established by Span 80 and
PC. SDC had a steroidal structure similar to the macrolide
tacrolimus and competed for the position in the bi-layered
vesicles. This displacement between species led to low EE%
to some extent [27].
3.1.2. Particle size
Therewere significant differences in particle size between TFs
consisting different surfactants. TFs containing SDC, Tween
80 and Span 80 expressed a mean particle size of 135.6, 123.1
and 260.6 nm, and the mean particle size of liposomes was
159.7 nm.
In general, particle size increased along with surfactants
possessing lower HLB. The trend between HLB and particle
size could be attributed to the increase in surface free energy
accompanying increasing hydrophobicity of surfactant. Sur-
factants interacted with lipid head groups in the membrane
would increase packing density of layer, which could lead to
high surface free energy [28]. Thus, the increasing surface free
energy led to fusion between lipid bilayers and larger size [29].
While Span 80 had the strongest hydrophobicity, the size
expansion of TFs-Span 80 was obviously compared with other
TFs.
3.1.3. Relative deformability
Deformability was one of the most important characteristics
for TFs to differ from other vesicles like liposomes. When
surrounding stress was enforced on vesicles to penetrate the
skin pores, TFs could spontaneously undergo deformation to
avoid the risk of structure rupture. Table 1 showed the rela-
tive deformability of TFs affected by different types of
surfactants.
DI% had a positive correlation with deformability. The
deformability of TFs was the 1.4e2.1 times that of the lipo-
somes. As described by Benson [30], the deformability of TFs
could attribute to the membrane fluidity. Membrane of TFs
was constituted by two amphiphilic components (PC plus
Fig. 1 e TEM morphology of TFs-Tween 80 (30,0003).
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 3 6e3 4 5340surfactant) which owned sufficiently different packing char-
acteristics and could transform bilayer structure into a single
layer. TFs-Tween 80 owned the highest deformability (DI: 9.22)
because Tween 80 had nonbulky hydrocarbon chains and no
steroid-like structure like SDC (DI: 6.25) that were unbeneficial
to membrane fluidity. TFs-Span 80 (DI: 7.93) showed the worst
deformability which could be a result of its high hydropho-
bicity. Its high hydrophobicity could reduce the formation of
transient hydrophilic holes which was responsible for mem-
brane fluidity [28].
3.1.4. Quantification of drug retained in skin in vitro
The effects of TFs containing different surfactants on
permeation in vitro were investigated. The amounts of tacro-
limus retained in skin for different vesicles were shown in
Table 1. TFs significantly enhanced the accumulation of drug
into the skin layers. Tacrolimus retention levels in skin of TFs
demonstrated 1.2e1.6 times higher than liposomes. Unlike
liposomes, TFs not only acted as drug vectors, but also acted
as penetration enhancers. Penetration enhancement could be
ascribed to the presence of surfactant contributing good
deformation to TFs [31, 32]. TFs dispersions were partly
dehydrated by water evaporation after placed on the skin
surface, and transcutaneous hydration gradientwas produced
in skin [33]. The hydration gradient drove vesicles to carry
drug to enter the deeper skin avoiding dehydration and fusion
[16]. TFs owning better membrane deformability could pene-
trate the skin through the hydrophilic pathways or pore be-
tween the skin cells without losing its vesicle integrity. While
liposomes with less flexible bilayers would fracture during
transport through skin pore [34].
There existed apparently different drug retentions among
above TFs and the order was as follows: TFs-Tween 80
(6.66  0.68 mg/cm2) >TFs-Span 80 (5.87  0.51 mg/cm2) >TFs-
SDC (5.11  0.38 mg/cm2) >Liposomes (4.22  0.32 mg/cm2).
These significant variations were affected synthetically by EE
%, particle size and deformability. TFs-Tween 80 owned the
highest drug retentions. This could be explained by its small
particle size and good shape deformability which were bene-
ficial to delivering more tacrolimus through skin barrier and
depositing in skin. Our results were inconsistent with the
report by Jain et al. (Span 80 > SDC > Tween 80) [15]. This
observation probably argued on the differences in drug nature
between dexamethasone and tacrolimus.
However, the receptor fluid collected for TFs and common
liposomes did not detect the presence of any drug. This
might be explained that the amount of tacrolimus pene-
trating through skin and entering to receptor was tiny or
none. These results exactly corresponded with local use of
tacrolimus treating skin disease and didn’t cause system
adsorption [35].
3.2. Morphology observation
When all of these characterizations (EE%, particle size,
deformability index and drug retentions) were taken into ac-
counts together and more considerations were given to drug
retentions. TFs-Tween 80 was chosen as the optimal carrier
and used for further research. TEM for the TFs-Tween 80
dispersions exhibited typical single chamber structure (Fig. 1).3.3. In vitro drug release
TFs-Tween 80 and liposomes dispersions were prepared to gel
containing Carbopol 940 (1% wt). Both TFs-gel and
liposomes-gel displayed well adhesive capacity while
spreading over skin.
In vitro release studies of TFs-gel, liposomes-gel and mar-
keted ointment were investigated (Fig. 2). The drug release
from TFs-gel and liposomes-gel was 2.8 times and 2.3 times as
much as ointment (p < 0.05).
The release profiles of tacrolimus from TFs-gel and
liposomes-gel showed biphasic release processes [20], where
initial burst release of the surface-adsorbed drug was
observed, followed by slow diffusion from the lipid vesicles. At
the initial 4 h, the little higher drug release of liposomes-gel
was observed. This could be attributed to more unentrapped
drug distributing in the gel system as liposomes had a lower
EE%. Unentrapped drug could pass through release interface
earlier compared with drug entrapped in vesicles. Afterward,
lipid vesicles diffusion in gels played an important role in the
release profiles and drug release rate slowed down. The cu-
mulative drug release of TFs-gel, liposome-gel and ointment
were (116.72 7.49) mg, (95.75 5.89) mg and (41.34 3.59) mg in
24 h. TFs with higher EE% and better deformability could carry
more drugs through filters quickly as compared with
liposomes.3.4. Quantification of drug in different skin layers
In vivo skin retention experiments were conducted to further
study the distribution of tacrolimus in different skin layers
(SC, epidermal and dermal) after administration of TFs-gel,
liposomes-gel and ointment (Fig. 3). TFs-gel and liposomes-
gel obviously facilitated the penetration of tacrolimus into
skin as compared to ointment (p < 0.05).
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the SC, three final preparations displayed almost same dis-
tributions of tacrolimus. This phenomenon might indicate
that reservoir capacity of the SC arrive saturation state.
Tacrolimus mainly reserved in SC (as a drug deposit pool), on
account of SC lipid-rich environment. Then slow permeation
into the deeper epidermis and dermis would occur [36]. The
obtained results of the three preparations revealed that the
amounts of tacrolimus decreased gradually along with the
deeper layers (SC > epidermis > dermis) which was in agree-
ment with the findings of Betz et al. [37]. As diffusivity and
concentration of drug in deeper skin were small, the carriers
were hampered in further spontaneousmotion. Choi reported
TFs could carry drug to reach a depth of at least 30 mm [38]. In
the epidermis and dermis, amounts of tacrolimus for TFs-gel
were (1.73  0.21) mg/cm2 and (1.23  0.13) mg/cm2, which
were 3.8 times and 4.2 times as ointment.While liposomes-gel
were only 1.7 times and 1.4 times that of ointment (p < 0.05).
Liposomes would rupture while squeezing the nano-poresSC Epidermal Dermis
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Fig. 3 e The amount of drug retention different skin strata
in vivo skin retention experiments (n [ 6).which were much smaller than vesicles sizes due to their
rigid structures. They carried fewer amounts of applied drug
into the deeper layer. TFs could be released from gel system
and overcome the nano-porous barrier to follow the natural
water gradient across the epidermis by the greater flexibility
and movement of the bilayer. Then more drugs would be
transferred to deeper skin [39].
Like receptor fluid collected in vitro permeation studies,
blood collected in three preparations groups did not detect the
presence of any drug either.3.5. In vivo therapeutic efficacy
To evaluate the therapeutic effects of TFs-gel loaded tacroli-
mus on atopic dermatitis mice model, we investigated ear
swelling, morphological appearances and histopathological
features of treated skin. Liposomes-gel and ointment were
assessed in the same way.
Fig. 4 showed the ear swelling changes (including ear mass
and thickness) in the whole experiments. The significantly
increasing ear swelling after stimulation was one of
Fig. 5 e The mice skin histopathological images of different groups (n [ 10).
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After repeated administrations for seven days, TFs-gel dis-
played the best therapeutic effects by depressing ear swelling
to the minimum, as compared with other preparations. Ear
thickness decreased from0.486mmto 0.347mm,and earmass
cut down from 16.08mg to 11.43mg. Liposomes-gel expressed
a slightly better effect than ointmentwhichwas reported to be
clinically effective and safe for atopic dermatitis [41].
Stimulation with DNFB for several times, dorsal dermal of
model mice appeared erythema, edemaand scabs. Besides,
scratching behaviors was obviously. Histopathological images
(Fig. 5) showed significant thickening of the skin layers, as well
as an accumulation of inflammatory cell nucleus in the
inflamed skin layer. These pathological changes were in
accordance with the previous literatures [42].
As was shown in Fig. 6, after administration with TFs-gel
for 7 days, injured skin started to get better and enabled the
wound to grow scab. Then scabs exuviated and exposed thehealing skin. New hair began to grow at most of damaged skin
surface. The histopathology of the skin showed the thickness
of skin layer became significantly thinner and the amounts of
inflammatory cell nucleus reduced. Part of the skin surface of
liposomes-gel group grew new hair and skin layers were
thicker than TFs-gel. Ointment group didn’t yet grow new hair
and inflammatory cell nucleus infiltration was still evident.
Liposomes-gel and ointment took effect slowly as compared
to TFs-gel.
These results verified the retentions of tacrolimus in
different skin layers for three preparations. TFs-gel carried
more tacrolimus into deeper layer and took effects quickly.
Tacrolimus was an anti-T-cell drug and suppressed the
release of inflammatory cytokine whichwas necessary for the
immediate and chronic allergic reactions of inflammatory
cells [43]. All tacrolimus-loaded preparations decreased
thickening of the epidermis/dermis and suppressed the in-
crease of inflammatory cells at affected sites.
Fig. 6 e The mice dorsal skin morphological changes of different groups (n [ 10).
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In this work, TFs displayed special deformability responding
to an external stress and worked as an enhancer of percuta-
neous penetration. Different types of surfactants for TFs could
lead to distinct entrapment efficiency, diameter, deform-
ability and drug retentions. Tween 80 was more effective for
TFs to load tacrolimus as compared to other surfactants.Tacrolimus could be entrapped into TFs with good
deformability to penetrate skin pores much narrower than
vesicles diameter. More drugs could be transported to deeper
skin layers. TFs-gel loaded tacrolimus displayed more effec-
tive retentions in epidermis and dermis compared with
traditional liposomes-gel and commercial ointment. In vivo
therapy of mice dermatitis, TFs-gel took effect more quickly
than liposomes-gel and commercial ointment. Ear swelling
a s i a n j o u rn a l o f p h a rma c e u t i c a l s c i e n c e s 8 ( 2 0 1 3 ) 3 3 6e3 4 5344and pathological skin were improved markedly. We could
conclude that TFs might be a useful carrier for tacrolimus to
treat for atopic dermatitis.
In further study, CLSM (confocal laser scan microscope)
could be used to visualize the cutaneous uptake and confirm
target to deeper skin layers. The drug retentions in patholog-
ical changes skin with AD also should be determined, as
permeability barrier of diseased skin were different from the
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